Myocardial resistance to ischemic and reperfusion injuries under conditions of chronic administration of opioid receptor agonists and antagonists

Bulletin of Experimental Biology and Medicine

Volumn 145, Issue 6, 2008, Pages 696-699

  Lishmanov, Yu B ^a   Stakheev, D L ^a   Krylatov, A V ^a   Naryzhnaya, N V ^a   Maslov, L N ^a   Ovchinnikov, M V ^a   Kolar, F ^b,c  

^a CARDIOLOGY RESEARCH INSTITUTE   (Russian Federation)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^c INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

Chronic treatment with opioid receptor agonists; Ischemia; Myocardium; Reperfusion

Indexed keywords

4 [(3,4 DICHLOROPHENYL)ACETYL] 3 (1 PYRROLIDINYLMETHYL) 1 PIPERAZINECARBOXYLIC ACID METHYL ESTER; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; MU OPIATE RECEPTOR; NALTREXONE; OPIATE AGONIST; OPIATE ANTAGONIST; QUADAZOCINE;

ANIMAL EXPERIMENT; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; IN VIVO STUDY; MALE; NONHUMAN; RAT; REPERFUSION INJURY;

ANIMALS; AZOCINES; ENKEPHALIN, LEUCINE-2-ALANINE; HEART; MALE; MYOCARDIAL REPERFUSION INJURY; NALTREXONE; PIPERAZINES; PYRROLIDINES; RATS; RATS, WISTAR; RECEPTORS, OPIOID; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

RATTUS;

EID: 56049095550     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-008-0172-9     Document Type: Article

References (14)

1. A. G. Gorgaslidze, M. A. Saifulaeva, M. M. Kuz'mina, et al., Kardiologiya, No. 1, 14-16 (1993).
2. N. V. Korobov, Farmakol. Toksikol., No. 4, 35-38 (1988).
3. Yu. B. Lishmanov, L. N. Maslov, and K. Rais, Eksp. Klin. Farmakol., 65, No. 4, 71-77 (2002).
4. L. N. Maslov, E. I. Barzakh, A. A. Platonov, et al., Byull. Eksp. Biol. Med., 140, No. 12, 633-638 (2005).
5. P. J. Birch, H. Rogers, A. G. Hayes, et al., Br. J. Pharmacol., 103, No. 3, 1819-1823 (1991).
6. E. R. Butelman, M. C. Holden, O. Ko, et al., J. Pharmacol. Exp. Ther., 298, No. 3, 1049-1059 (2001).
7. M. Y. Chan, S. Dai, and W. W. Ko, Br. J. Pharmacol., 90, No. 3, 537-543 (1987).
8. L. A. Dykstra, D. E. Gmerek, G. Winger, and J. H. Woods, J. Pharmacol. Exp. Ther., 242, No. 2, 421-427 (1987).
9. C. Ela, J. Barg, Z. Vogel, et al., J. Mol. Cell. Cardiol., 29, No. 2, 711-720 (1997).
10. S. S. Negus, T. F. Burke, F. Medzihradsky, and J. H. Woods, J. Pharmacol. Exp. Ther., 267, No. 2, 896-903 (1993).
11. J. N. Peart, E. R. Gross, and G. J. Gross, J. Cardiovasc. Pharmacol., 43, No. 3, 410-415 (2004).
12. J. E. Schultz, A. K. Hsu, and G. J. Gross, J. Mol. Cell. Cardiol., 29, No. 8, 2187-2195 (1997).
13. J. E. Schultz, Y. Z. Qian, G. J. Gross, and R. C. Kukreja, Ibid., No. 3, pp. 1055-1060.
14. R. Tao, M. Karnik, Z. Ma, and S. B. Auerbach, Br. J. Pharmacol., 139, No. 8, 1498-1504 (2003).